Should You Buy CRISPR Therapeutics AG (CRSP) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor who is impatient. CRSP’s longer-term moving averages are still bullish, but near-term momentum is weakening (negative, expanding MACD histogram) while insiders are aggressively selling. With price sitting below the pivot (~55.65) and an earnings catalyst coming on 2026-02-19, the setup favors waiting rather than buying immediately.
Technical Analysis
Trend/price location: CRSP is ~53.7–54.0 post-market, below the pivot (55.647) and closer to support (S1 51.88; S2 49.554) than resistance (R1 59.414). Momentum: MACD histogram -0.105 and negatively expanding signals weakening near-term momentum. RSI(6)=42.2 is neutral-to-soft (not oversold). Moving averages: SMA_5 > SMA_20 > SMA_200 is structurally bullish, but the bearish MACD suggests the uptrend is currently losing steam. Intellectia Proprietary Trading Signals: **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently. Pattern-based projection provided: model suggests positive drift (2.6% next week; 15.53% next month), but current momentum indicators do not confirm a clean entry today.
Analyst Ratings and Price Target Trends
Recent analyst trend: price targets have been repeatedly trimmed (Citi 87→77; Chardan 82→74; JPM 70→69; BofA 93→90→89), while many firms maintain Buy/Overweight ratings—signaling continued long-term optimism but reduced near-term expectations (notably around Casgevy). Mixed stance among the street: bulls emphasize platform/pipeline and eventual sequential growth; more cautious firms (Neutral/Hold/Sector Perform) cite uncertainty around the launch ramp and desire for clearer inflection points. Influence/flow checks: Hedge funds are described as neutral with no major trend; no recent congress trading data available.
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 54.260
Current: 54.260
